Added to YB: 2026-09-24
Pitch date: 2026-09-18
NUVB [bullish]
Nuvation Bio Inc.
-4.83%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Market Cap
$2.1B
Pitch Price
$6.00
Price Target
10.91 (+79%)
Dividend
N/A
EV/EBITDA
-13.57
P/E
-13.34
EV/Sales
10.65
Sector
Pharmaceuticals
Category
growth
Nuvation Bio ($NUVB) : The bane of rare cancers?
NUVB: Nuvation has shifted from failed internal discovery to a rapidly scaling oncology launch, yet is valued like a high-burn, pre-revenue biotech. IBTROZI’s expanded FDA label shows a 90.3% front-line response rate and 49.7-month median response duration; Q2 product sales rose 25% sequentially to $23.2M. A $970M pro forma liquidity cushion supports runway past 2029. The $10.91 target implies 79% upside, with formulary resistance and safusidenib’s unresolved high-risk astrocytoma profile the key risks.
Read full article (5 min)